Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Bilirubin Level is Associated with Left Ventricular Hypertrophy Independent of Blood Pressure in Previously Untreated Hypertensive Patients

  • Ayaz, Teslime (Department of Internal Medicine, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Durakoglugil, Murtaza Emre (Department of Cardiology, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Kocaman, Sinan Altan (Department of Cardiology, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Durakoglugil, Tugba (Department of Radiology, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Erdogan, Turan (Department of Cardiology, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Sahin, Osman Zikrullah (Department of Internal Medicine, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Sahin, Serap Baydur (Department of Internal Medicine, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Cicek, Yuksel (Department of Cardiology, Recep Tayyip Erdogan University, Education and Research Hospital) ;
  • Satiroglu, Omer (Department of Cardiology, Recep Tayyip Erdogan University, Education and Research Hospital)
  • Received : 2014.04.20
  • Accepted : 2014.08.19
  • Published : 2014.05.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Left ventricular hypertrophy (LVH), a sign of subclinical cardiovascular disease, is an important predictor of cardiovascular morbidity and mortality. The aim of our study was to determine the association of left ventricular mass (LVM) with possible causative anthropometric and biochemical parameters as well as carotid intima-media thickness (CIMT) and brachial flow-mediated dilation (FMD) as surrogates of atherosclerosis and endothelial dysfunction, respectively, in previously untreated hypertensive patients. Subjects and Methods: Our study included 114 consecutive previously untreated hypertensive patients who underwent echocardiography and ultrasonography to evaluate their vascular status and function via brachial artery CIMT and FMD. Results: Among all study parameters, age, systolic blood pressure (BP), diastolic BP, pulse pressure, plasma glucose, uric acid, total bilirubin, direct bilirubin, hemoglobin, and CIMT were positively correlated with the LVM index. Multiple logistic regression analysis revealed that office systolic BP, age, male gender, and total bilirubin were independent predictors of LVH. Conclusion: Bilirubin seems to be related to LVM and LVH. The positive association of bilirubin with these parameters is novel and requires further research.

Keywords

References

  1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6. https://doi.org/10.1056/NEJM199005313222203
  2. Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA 2004;292:2396-8. https://doi.org/10.1001/jama.292.19.2396
  3. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9. https://doi.org/10.1001/jama.292.19.2343
  4. Levy D, Murabito JM, Anderson KM, Christiansen JC, Castelli WP. Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study. Clin Exp Hypertens A 1992;14:85-97.
  5. Savage DD, Levy D, Dannenberg AL, Garrison RJ, Castelli WP. Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990;65:371-6. https://doi.org/10.1016/0002-9149(90)90304-J
  6. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007;17:409-14. https://doi.org/10.1016/j.numecd.2007.02.011
  7. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol 2012; 59:235-42. https://doi.org/10.1016/j.jjcc.2012.01.013
  8. Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013;52:127-34. https://doi.org/10.1093/rheumatology/kes223
  9. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235: 1043-6. https://doi.org/10.1126/science.3029864
  10. Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012;126:2556-64. https://doi.org/10.1161/CIRCULATIONAHA.112.114066
  11. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16: 250-5. https://doi.org/10.1161/01.ATV.16.2.250
  12. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007;28:850-6. https://doi.org/10.1093/eurheartj/ehm026
  13. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004;109(25 Suppl 1):IV22-30.
  14. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
  15. Onat A, Hergenc G, Can G. [Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition]. Anadolu Kardiyol Derg 2007;7:29-34.
  16. Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intimamedia thickness. J Intern Med 2005;257:430-7. https://doi.org/10.1111/j.1365-2796.2005.01485.x
  17. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
  18. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009;52:153-67. https://doi.org/10.1016/j.pcad.2009.05.002
  19. Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. J Am Soc Hypertens 2011;5:449-55. https://doi.org/10.1016/j.jash.2011.08.006
  20. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45:18-20. https://doi.org/10.1161/01.HYP.0000150785.39055.e8
  21. Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006; 19:1055-62. https://doi.org/10.1016/j.amjhyper.2006.02.014
  22. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006;47:195-202. https://doi.org/10.1161/01.HYP.0000200033.14574.14
  23. Tsioufis C, Chatzis D, Vezali E, et al. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens 2005;19:211-7. https://doi.org/10.1038/sj.jhh.1001810
  24. Cuspidi C, Valerio C, Sala C, et al. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens 2007; 20:678-85. https://doi.org/10.1016/j.amjhyper.2007.01.013
  25. Osgood K, Krakoff J, Thearle M. Serum uric acid predicts both current and future components of the metabolic syndrome. Metab Syndr Relat Disord 2013;11:157-62. https://doi.org/10.1089/met.2012.0151
  26. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008;60:79-127. https://doi.org/10.1124/pr.107.07104
  27. Hu CM, Chen YH, Chiang MT, Chau LY. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 2004;110:309-16. https://doi.org/10.1161/01.CIR.0000135475.35758.23
  28. Ndisang JF, Jadhav A. Upregulating the heme oxygenase system suppresses left ventricular hypertrophy in adult spontaneously hypertensive rats for 3 months. J Card Fail 2009;15:616-28. https://doi.org/10.1016/j.cardfail.2009.02.003
  29. Diaz-Gil JJ, Gavilanes JG, Garcia-Canero R, et al. Liver growth factor purified from human plasma is an albumin-bilirubin complex. Mol Biol Med 1989;6:197-207.
  30. Conde MV, Gonzalez MC, Quintana-Villamandos B, et al. Liver growth factor treatment restores cell-extracellular matrix balance in resistance arteries and improves left ventricular hypertrophy in SHR. Am J Physiol Heart Circ Physiol 2011;301:H1153-65. https://doi.org/10.1152/ajpheart.00886.2010

Cited by

  1. Relationship between Serum Bilirubin and Left Ventricular Hypertrophy in Patients with Essential Hypertension vol.10, pp.4, 2014, https://doi.org/10.1371/journal.pone.0125275
  2. Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea vol.315, pp.3, 2014, https://doi.org/10.1152/ajpheart.00417.2017
  3. Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure vol.22, pp.7, 2021, https://doi.org/10.3390/ijms22073321
  4. Bilirubin and cardiovascular risk vol.26, pp.9, 2014, https://doi.org/10.15829/1560-4071-2021-4511